Skip to main content
. Author manuscript; available in PMC: 2014 Aug 21.
Published in final edited form as: Expert Rev Gastroenterol Hepatol. 2014 Feb 4;8(3):223–240. doi: 10.1586/17474124.2014.881715

Table 7.

Risk of progressive multifocal leukoencepholopathy in John Cunningham virus antibody-positive patients exposed to natalizumab.

Exposure (months) No prior IS use Prior IS use
1–24 0.5/1000 1.5/1000
25+ 3.9/1000 10.6/1000

IS: Immune suppressant.

Data taken from [151].